Transcranial Magnetic Stimulation No Better Than Placebo for Treatment-Resistant Depression
A new study in JAMA Psychiatry found that transcranial magnetic stimulation was no better than placebo for treatment-resistant depression.
New Study Casts Doubt on Efficacy of Ketamine for Depression
A new study, published this month in the Journal of Affective Disorders, investigated the effectiveness of weekly intravenous ketamine injections as a treatment for...
Garbage InâGarbage Out: Systematic Reviews and Meta-Analyses can tell us a Flawed Story
Well known Stanford University researcher John Ioannidis published a new paper this week criticizing the use and production of systematic reviews and meta-analyses, often...
Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
Has Evidence Based Medicine Been Hijacked?
John Ioannidis claims that the idea of evidence based medicine has been âhijacked to serve agendas different from what it was originally aimed for,â in a newly published critical essay in the Journal of Clinical Epidemiology. Ioannidis frames the essay as a continuation of a conversation with David Sackett, widely considered the founder of evidence based medicine.
Researchers Search for Subgroups Where Antidepressants Are More Effective
The researchers theorized that this increased effectiveness was due not to âantidepressantâ properties, but rather to the drugâs side effects, which include insomnia, drowsiness, and nausea.
NICE Guideline Update Acknowledges Severe Antidepressant Withdrawal
A new update to the NICE guideline for depression suggests providers discuss long-term, severe antidepressant withdrawal symptoms.
New Study Concludes that Antidepressants are “Largely Ineffective and Potentially Harmfulâ
A new study published in Frontiers in Psychiatry concludes that âantidepressants are largely ineffective and potentially harmful.â
Review Explores First-Person Experiences of People Taking Antipsychotics
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
Is Long-term Use of Benzodiazepines a Risk for Cancer?
A large study of the population in Taiwan reveals that long-term use of benzodiazepine drugs, commonly prescribed for anxiety, significantly increases the risk for brain, colorectal, and lung cancers. The research, published open-access in the journal Medicine, also identifies the types of benzodiazepines that carry the greatest cancer risk.
Cognitive Impairment from Long-Term Benzodiazepine Use Remains Even After Drug Withdrawal
Long-term benzodiazepine use shown to effect cognitive function during current use and for years after drug discontinuation.
Antidepressant Use Leads to Worse Long Term Outcomes, Study Finds
Results from a 30-year prospective study demonstrated worse outcomes for people who took antidepressants, even after controlling for gender, education level, marriage, baseline severity, other affective disorders, suicidality, and family history of depression.
Researcher Acknowledges His Mistakes in Understanding Schizophrenia
Sir Robin Murray, a professor at the Institute of Psychiatry, Psychology, and Neuroscience in London, states that he ignored social factors that contribute to âschizophreniaâ for too long. He also reports that he neglected the negative effects antipsychotic medication has on the brain.
Psychotropic Medications Serve as Powerful Tools for U.S. Military, Imperialism
Ethnographic research sheds light on extensive psychopharmaceutical use by soldiers in post 9/11 U.S. wars.
Scientists Clarify Risks of Augmenting with Antipsychotic Medications for Depression
The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.
Members of FDA Advisory Committee Offer Perspectives on Flibanserin Approval in JAMA
In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committeeâs recommendation to approve flibanserin especially challenging and politically charged.
Study Links SSRIs to Violent Crime in Youth
Individuals between the ages of 15 and 24 are more likely to commit a violent crime if they are taking an SSRI antidepressant than if they are not, according to new research out of Sweden. The study published in PLoS Medicine on Tuesday, suggests "warnings about the increased risk of violent behavior among young people taking SSRIs might be needed.â
Antidepressant Misinformation Promoted on Popular Websites
A new study indicates that popular online resources do not accurately present the scientific evidence on the risks and benefits of antidepressants.
Olanzapine Can Cause Serious Skin Reaction, FDA Warns
The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...
Researchers Expose Pharmaceutical Industry Misconduct and Corruption
Corruption of pharmaceutical industry sponsored clinical trials identified as a âmajor obstacleâ facing evidence-based medicine.
Study Finds ADHD Drugs Alter Developing Brain
A new study, published in the JAMA Psychiatry, investigates the effect of stimulant âADHDâ drugs on the brains of children and young adults. The...
Vitamin B6 Effective in Reducing Antipsychotic Induced Akathisia
A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.
Very Slow Tapering Best For Antidepressant Withdrawal
A new article in Lancet Psychiatry finds that slower tapering of SSRIs is better for preventing antidepressant withdrawal effects.
Gradual Tapering is Most Successful for Withdrawal from Antipsychotics
Mixed-Methods study explores the experiences of antipsychotic discontinuation among service users.
New Clinical Guidelines on Deprescribing Benzodiazepines
New guidelines recommend deprescribing benzodiazepine receptor agonists for adults.
